Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource® LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Resources

PER Pulse™ Recaps for Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie; Astellas; AstraZeneca; Exelixis, Inc; Ferring Pharmaceuticals, Inc; Genomic Health, Inc; Medivation, Inc, a Pfizer Company; and Merck Sharp & Dohme Corp.

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies

Release Date: May 30, 2017
Expiration Date: May 30, 2018
Media: Internet - based

 

Activity Overview

This interactive, case-based activity focuses on multidisciplinary standards of care and emerging strategies in the treatment of prostate cancer, renal cell carcinoma, and bladder cancer. It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in March 2017 at New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. In their interviews, program co-chairs Daniel Petrylak, MD, and Leonard Gomella, MD, along with faculty David Quinn, MD, MBBS, PhD, offer guidance and perspective on standards of care, the clinical implication of new data, and novel investigational agents and approaches. This activity is geared to meet the needs of busy clinicians who strive to advance the management of patients with genitourinary malignancies.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie; Astellas; AstraZeneca; Exelixis, Inc; Ferring Pharmaceuticals, Inc; Genomic Health, Inc; Medivation, Inc, a Pfizer Company; and Merck Sharp & Dohme Corp.

CME/CE Activity Table of Contents

  • Case 1: Metastatic, Post-Platinum, Urothelial Cancer
    Daniel Petrylak, MD
  • Case 2: Metastatic Renal Cell Carcinoma After TKI Failure
    David Quinn, MD, MBBS, PhD
  • Case 3: Early Prostate Cancer
    Leonard Gomella, MD
  • Case 4: Prostate Cancer: High PSA Level With Involvement of Retroperitoneal and Periaortic Lymph Nodes
    Leonard Gomella, MD
  • Case 5: Metastatic Castration-Resistant Prostate Cancer
    Daniel Petrylak, MD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision making in the management of genitourinary (GU) malignancies
  • Summarize recommendations that shape current strategies to care for patients with GU malignancies
  • Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related adverse effects in caring for patients with GU malignancies
  • Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage GU malignancies
  • Apply emerging clinical concepts to support the management of GU malignancies in consideration of evolving treatment paradigms in the field

Faculty, Staff, and Planners' Disclosures

Faculty

Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA

Disclosure: Consultant: Astellas, Bayer, MDxHealth, Janssen, Merck, Pfizer

Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosure: Grant Research Support: OncoGeneX, Progenics, Johnson & Johnson, Merck, Millennium, Dendreon, Sanofi, Agensys, Eli Lilly, Roche Laboratories; Consultant: Bayer, Bellicum, Dendreon, Sanofi, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Time Technologies; Speaker: Bellicum, Tyme

David I. Quinn, MD, MBBS, PhD, FRACP, FACP
Associate Professor of Medicine
Section Head, Genitourinary Oncology,
Division of Cancer Medicine and Blood Diseases
in The Department of Medicine
University of Southern California

Disclosure: Grant Research Support: Millennium, Genentech, GlaxoSmithKline; Consultant: Astellas, Bayer, Pfizer, Novartis, Bristol-Myers Squibb, Genentech, Merck, EMD Serono, Exelixis, Peloton, Vertex, Dendreon

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma after tyrosine kinase inhibitor failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Petrylak, during which he discussed:

  • His approach toward a 72-year-old female who had a history of myocardial infarction, hypertension, and obesity, as well as metastatic bladder cancer that had progressed 8 months after completion of gemcitabine/cisplatin therapy
  • Clinical landscape regarding biomarkers in bladder cancer:
    • Mutational burden and bladder cancer subtype are promising biomarkers.
    • PD-L1 status alone is not sufficient to predict response.
  • Trials of checkpoint inhibition therapy plus radiation therapy in the upfront setting that aim to exploit the abscopal effect
  • Lack of standard treatment for patients with high-risk bladder cancer who have received neoadjuvant chemotherapy; checkpoint inhibitory therapy is being investigated in the adjuvant setting for these patients.

2 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma (RCC) after tyrosine kinase inhibitor (TKI) failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Quinn, during which he discussed:

  • His approach toward a 54-year-old male with metastatic clear-cell RCC (post-nephrectomy) that progressed while receiving first-line sunitinib
  • Specific factors that might influence treatment selection for patients with metastatic clear-cell RCC (eg, pace of progression, symptoms, physician bias)
  • Potential implications of the CABOSUN trial on subsequent lines of therapy (eg, sequencing of nivolumab, other VEGFR TKIs, lenvatinib + everolimus)
  • How the potential use of adjuvant sunitinib (based on S-TRAC trial data) would affect treatment algorithms in the metastatic setting
  • Continuation of a checkpoint inhibitor for a patient with stable disease or subtle progression, and switching therapy for a patient with symptomatic progression or who is not tolerating the therapy
  • Anecdotal experiences with patients who have discontinued checkpoint inhibitor therapy after achieving a major response

3 of 3
PER Pulse™ Recap

Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an online educational activity that features a series of short video interviews with expert faculty, who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the live congress. The online activity features discussion on:

  • Metastatic, post-platinum urothelial cancer, by Daniel Petrylak, MD
  • Metastatic renal cell carcinoma after tyrosine kinase inhibitor failure, by David Quinn, MD, MBBS, PhD
  • Early prostate cancer, by Leonard Gomella, MD
  • Prostate cancer with high prostate-specific-antigen (PSA) level and involvement of retroperitoneal and periaortic lymph nodes, by Leonard Gomella, MD
  • Metastatic castration-resistant prostate cancer, by Daniel Petrylak, MD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Gomella, during which he discussed:

  • His approach toward a 57-year-old patient with prostate cancer (perineural invasion, 2.5-cm periaortic lymph nodes, and enlarged prostate; PSA, 45 ng/mL; Gleason score, [4+5])
  • Unclear benefit of adding local or systemic therapy to standard androgen-deprivation therapy in the setting of low-volume, castration-naïve, metastatic prostate cancer
  • His approach when progression is limited to biochemical failure
  • Factors that influence his selection of an androgen-deprivation agent (eg, testosterone level, critical spinal cord lesion, impending fracture)
  • Essentials that a urologist should know about immunotherapy in genitourinary malignancies






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By